BioWorld: The Daily Biopharmaceutical and Medical Technology …
Ring Therapeutics Inc. has joined forces with Singapore’s Agency for Science, Technology, and Research and with the Singapore Eye Research Institute to advance the first... In the newest BioWorld Insider podcast, Victoria Lipinska, the America's lead for Quantum Innovation Centers at IBM Quantum, talks about the future of drug development ...
Media and podcasts - BioWorld
BioWorld Insider Podcast. One-on-one with medical innovators. Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating ...
BioWorld MedTech: The Daily Medical Technology News Source
Med-tech funding rises, driven by private investments and follow-ons. Med-tech firms raised $22.71 billion in financings through October, an increase of 46% over the $15.59 billion raised during the same period in 2023. October’s value totaled $1.43 billion, up from $1.02 billion in September, but down from August's $3.67 billion.
US FDA clears Cobenfy, first new schizophrenia drug in decades
Sep 27, 2024 · The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the first to act via a novel mechanism for the serious psychiatric disorder in over 50 years, finally expanding the treatment options beyond dopamine-targeted therapies.
China - Articles - BioWorld
Nov 6, 2024 · Oct. 21, 2024. By Tamra Sami. No Comments. After raising $42 million in a series C1 round, Lanova Medicines Ltd. is advancing its lead phase III antibody-drug conjugate LM-302 that targets Claudin 18.2, as well as LM-299, an anti-PD-1/VEGF bispecific antibody, and LM-108, an anti-CCR8 monoclonal antibody.
| BioWorld
Aug. 11, 2022. Aro Biotherapeutics announced that the FDA has granted orphan drug designation for ABX-1100, its investigational Centyrin-siRNA conjugate, for the treatment of Pompe disease. BioWorld Science Endocrine/metabolic. After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs ...
Apimeds prices $11.5M IPO for bee venom-based therapy
Sep 30, 2024 · Apimeds prices $11.5M IPO for bee venom-based therapy. Apimeds Pharmaceuticals US Inc., a subsidiary of Seoul, South Korea-based Inscobee Inc., is “counting down” to an official IPO on the New York Stock Exchange with its S-1 filing showing a targeted offering of $11.5 million. Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli ...
| BioWorld
May 14, 1992 · Scios Inc. and Nova Pharmaceutical Corp. announced onWednesday that they will merge in an exchange of stockvalued at $180 million. The company, to be called Scios-Nova Inc., will combine Scios'expertise in biotechnology with Nova's strength in smallmolecules, receptor technology and rational drug design, saidRichard Casey, president and chief executive of Scios.
Australia - Articles - BioWorld
Oct. 8, 2024. By Tamra Sami. No Comments. Immunotherapy company Cartherics Pty Ltd. raised AU$15 million (US$10.3 million) in an oversubscribed series B round that will support the first clinical trial for lead chimeric antigen receptor natural killer therapy CTH-401 for ovarian cancer, and to expand its pipeline to include other diseases.
Newco news - Articles - BioWorld
Oct. 24, 2024. By Tamra Sami. No Comments. Hope Medicine Inc. reported positive interim results for monoclonal antibody HMI-115 in a phase II endometriosis trial that saw the mean non-menstrual pelvic pain score reduced by 50%. “HMI-115 is a prolactin receptor blocker, and we're using it to treat endometriosis and some other diseases.